124782-95-2

Basic information

• Product Name: 6-BROMO-2-PIPERAZIN-1-YL-QUINOLINE
• Synonyms: 6-BROMO-2-PIPERAZIN-1-YL-QUINOLINE;6-bromoquipazine;6-bromo-2-(piperazin-1-yl)quinoline(WX135275)
• CAS NO: 124782-95-2
• Molecular Formula: C13H14BrN3
• Molecular Weight: 292.17
• Mol File: 124782-95-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 451.8 °C at 760 mmHg
• Flash Point: 227 °C
• Appearance: /
• Density: 1.451 g/cm³
• Vapor Pressure: 2.37E-08mmHg at 25°C
• Refractive Index: 1.65
• CAS DataBase Reference: 6-BROMO-2-PIPERAZIN-1-YL-QUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2-PIPERAZIN-1-YL-QUINOLINE(124782-95-2)
• EPA Substance Registry System: 6-BROMO-2-PIPERAZIN-1-YL-QUINOLINE(124782-95-2)

Safety Data

• Hazardous Substances Data: 124782-95-2(Hazardous Substances Data)

Usage

General Description

6-Bromo-2-piperazin-1-yl-quinoline is a chemical compound with the molecular formula C14H14BrN3. It is a quinoline derivative that contains a piperazine moiety, making it a potential pharmacological agent. 6-BROMO-2-PIPERAZIN-1-YL-QUINOLINE has been investigated for its potential medicinal properties, including its activity as an antimalarial and antitumor agent. Its structure and properties make it a useful intermediate in the synthesis of various pharmaceutical compounds. Additionally, it may have potential applications in medicinal chemistry research and drug development.

InChI:InChI=1/C13H14BrN3/c14-11-2-3-12-10(9-11)1-4-13(16-12)17-7-5-15-6-8-17/h1-4,9,15H,5-8H2

Upstream product

• 1637483-39-6 tert-butyl 4-(6-bromoquinolin-2-yl)piperazine-1-carboxylate 
• 1810-71-5 6-bromo-2-chloroquinoline 
• 553-03-7 3,4-dihydro-2(1H)-quinolone 
• 3279-90-1 6-bromo-3,4-dihydro-1H-quinolin-2-one 

Relevant articles and documents

BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1

6-Nitroquipazine has been known as one of the most potent and selective inhibitors of serotonin transporter in vitro and in vivo. Nine derivatives of 6-nitroquipazine were synthesized and tested for their potential abilities to displace [3H]citalopram binding to the rat cortical membranes. (C) 2000 Elsevier Science Ltd. All rights reserved.